EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Novel HDAC8 Inhibitors Through Shape-Based Virtual Screening: Experimental Validation and Characterization of a Promising Quinoline-Based Hit Scaffold

Adriana Gargano iD, Aday González-Bakker iD, Adrián Puerta iD, Valentina Maggisano, Stefania Bulotta, Roberta Rocca iD, José M Padrón iD, Stefano Alcaro iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27219557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Adriana Gargano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze della Salute, Università "Magna Græcia" di Catanzaro, Campus Universitario "S. Venuta", Viale Europa, 88100 Catanzaro, Italy. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Repressor Proteins, Quinolines, Histone Deacetylases. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación, Spanish Association Against Cancer, Spanish Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylase 8 (HDAC8) is overexpressed in several solid tumors and, unlike other Class I HDACs, functions independently of large corepressor complexes, making it an attractive target for structure-based drug design. Here, we aimed to identify novel natural compounds capable of targeting the human HDAC8 catalytic site. A library of 307,814 natural products from ZINC15 was screened by shape-based virtual screening using five structurally diverse co-crystallized HDAC8 ligands as templates, followed by molecular docking and Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) binding free energy calculations. Seven commercially available hits were selected for enzymatic validation, leading to the identification of 4-((7-methoxyquinolin-4-yl)amino)benzamide (ZINC000054202375, compound 2) as a promising HDAC8 inhibitor. In vitro antiproliferative assays across multiple human solid tumor cell lines demonstrated significant growth inhibition by compound 2, further supported by colony formation assays. Mechanistic studies using label-free live-cell imaging, Annexin V staining, DAPI (4′,6-diamidino-2-phenylindole) nuclear morphology, and DCFDA (2′,7′-dichlorodihydrofluorescein diacetate) assays revealed membrane blebbing, mitotic failure, increased reactive oxygen species, and nuclear fragmentation, consistent with apoptosis induction. Finally, 1 μs molecular dynamics simulations supported the formation of a persistent ligand–receptor interaction network within the HDAC8 catalytic pocket. Overall, compound 2 represents a promising non-hydroxamate hit scaffold with promising HDAC8 inhibitory activity, serving as a starting point for the development of novel HDAC-targeted anticancer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsRepressor ProteinsQuinolinesHistone DeacetylasesDrug DiscoveryHumansMolecular Docking SimulationCell Line, TumorCell ProliferationMolecular Dynamics SimulationAntineoplastic AgentsCatalytic DomainStructure-Activity Relationship

Stichwörter der Autor:innen

HDAC8 inhibitorsnatural compoundsshape virtual screening

Substanzen

HDAC8 protein, humanHistone Deacetylase InhibitorsRepressor ProteinsQuinolinesHistone DeacetylasesAntineoplastic Agentsquinoline

Autor:innen und Institutionen

  • Dipartimento di Scienze della Salute, Università "Magna Græcia" di Catanzaro, Campus Universitario "S. Venuta", Viale Europa, 88100 Catanzaro, Italy.
  • Associazione CRISEA-Centro di Ricerca e Servizi Avanzati per l'Innovazione Rurale, Località Condoleo, 88055 Belcastro, Italy.
  • BioLab, Instituto Universitario de Bio-Orgánica "Antonio González", Universidad de la Laguna, C/Astrofísico Francisco Sánchez 2, 38206 La Laguna, Spain.
  • Institute of Biological and Chemical Systems-Functional Molecular Systems, Karlsruhe Institute of Technology (KIT), 76344 Eggenstein-Leopoldshafen, Germany.

ORCID-Profile: Adriana Gargano, Aday González-Bakker, Adrián Puerta, Roberta Rocca, José M Padrón, Stefano Alcaro

Förderung

  • Agencia Estatal de Investigación
  • Spanish Association Against Cancer
  • Spanish Government
  • Asociación Española Contra el Cáncer

Zitieren

APA

Gargano, A., González-Bakker, A., Puerta, A., Maggisano, V., Bulotta, S., Rocca, R., Padrón, J. M., & Alcaro, S. (2026). Discovery of Novel HDAC8 Inhibitors Through Shape-Based Virtual Screening: Experimental Validation and Characterization of a Promising Quinoline-Based Hit Scaffold. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27219557

Vancouver

Gargano A, González-Bakker A, Puerta A, Maggisano V, Bulotta S, Rocca R, et al. Discovery of Novel HDAC8 Inhibitors Through Shape-Based Virtual Screening: Experimental Validation and Characterization of a Promising Quinoline-Based Hit Scaffold. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27219557

BibTeX
@article{Gargano2026,
  author = {Gargano, Adriana and González-Bakker, Aday and Puerta, Adrián and Maggisano, Valentina and Bulotta, Stefania and Rocca, Roberta and Padrón, José M and Alcaro, Stefano},
  title = {Discovery of Novel HDAC8 Inhibitors Through Shape-Based Virtual Screening: Experimental Validation and Characterization of a Promising Quinoline-Based Hit Scaffold},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27219557}
}
Kostenlos starten →